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Abstract
Background: Osteopoikilosis is a rare autosomal dominant genetic disorder, characterised by the occurrence of the 
hyperostotic spots preferentially localized in the epiphyses and metaphyses of the long bones, and in the carpal and 
tarsal bones [1]. Heterozygous LEMD3 gene mutations were shown to be the primary cause of the disease [2]. 
Association of the primarily asymptomatic osteopokilosis with connective tissue nevi of the skin is categorized as 
Buschke-Ollendorff syndrome (BOS) [3]. Additionally, osteopoikilosis can coincide with melorheostosis (MRO), a more 
severe bone disease characterised by the ectopic bone formation on the periosteal and endosteal surface of the long 
bones [4-6]. However, not all MRO affected individuals carry germ-line LEMD3 mutations [7]. Thus, the genetic cause of 
MRO remains unknown. Here we describe a familial case of osteopoikilosis in which a novel heterozygous LEMD3 
mutation coincides with a novel mutation in EXT1, a gene involved in aetiology of multiple exostosis syndrome. The 
patients affected with both LEMD3 and EXT1 gene mutations displayed typical features of the osteopoikilosis. There 
were no additional skeletal manifestations detected however, various non-skeletal pathologies coincided in this group.
Methods: We investigated LEMD3 and EXT1 in the three-generation family from Poland, with 5 patients affected with 
osteopoikilosis and one child affected with multiple exostoses.
Results: We found a novel c.2203C > T (p.R735X) mutation in exon 9 of LEMD3, resulting in a premature stop codon at 
amino acid position 735. The mutation co-segregates with the osteopoikilosis phenotype and was not found in 200 
ethnically matched controls. Another new substitution G > A was found in EXT1 gene at position 1732 (cDNA) in Exon 9 
(p.A578T) in three out of five osteopoikilosis affected family members. Evolutionary conservation of the affected amino 
acid suggested possible functional relevance, however no additional skeletal manifestations were observed other then 
those specific for osteopoikilosis. Finally in one member of the family we found a splice site mutation in the EXT1 gene 
intron 5 (IVS5-2 A > G) resulting in the deletion of 9 bp of cDNA encoding three evolutionarily conserved amino acid 
residues. This child patient suffered from a severe form of exostoses, thus a causal relationship can be postulated.
Conclusions: We identified a new mutation in LEMD3 gene, accounting for the familial case of osteopoikilosis. In the 
same family we identified two novel EXT1 gene mutations. One of them A598T co-incided with the LEMD3 mutation. 
Co-incidence of LEMD3 and EXT1 gene mutations was not associated with a more severe skeletal phenotype in those 
patients.
Background
Osteopoikilosis is a rare and primarily benign autosomal
dominant genetic entity caused by heterozygous muta-
tions in the LEMD3 gene. It is characterised by the occur-
rence of the hyperostotic spots throughout the skeleton,
with most frequent localization in the epiphyses and
metaphyses of the long bones, as well as in the carpal and
tarsal bones [1]. The clinical features of osteopoikilosis
are relatively mild, therefore the condition is usually diag-
nosed by chance or because of the association with other
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medical problems (fractures, joint dislocations, etc.). In
addition to spotty bone changes, some patients affected
by osteopoikilosis develop the superficial skin lesions
(elastic-type nevi) and/or subcutaneous foci of dermato-
fibrosis. Such combination of clinical features is catego-
rized as a separate condition named the Buschke-
Ollendorff syndrome [3]. Osteopoikilosis has also been
found in association with a more severe and detrimental
bone disease called melorheostosis. Melorheostosis man-
ifests with predominantly asymmetric depositions of
dense compact bone on the periosteal and endosteal sur-
face of the long bones, resembling a dripping wax of a
candle. Bone deformations are often associated with the
ossification of the soft tissue in the joint proximity, which
can cause compression of the adjacent nerves, and result
in pain. Heterozygous LEMD3  gene mutations were
d e t e c t e d  i n  a l l  s u c h  c a s e s .  I n  c o n t r a s t ,  n o  g e r m l i n e
LEMD3  mutations were found in the isolated cases of
melorheostosis [7,8]. Thus, genetic cause of isolated
melorheostosis remains unknown. Melorheostosis
belongs to a group of osteogenic lesions together with
another disease called hereditary multiple exostoses
(HME) [9]. Multiple exostoses (enchondromas) are
caused by heterozygous mutations in EXT1, EXT2 and/or
EXT3 genes. The EXT proteins function in the proteogly-
can synthesis and play tumour suppressor roles. EXT1
and EXT2 have both been shown to encode a heparan
sulphate polymerase with both D-glucuronyl (GlcA) and
N-acetyl-D-glycosaminoglycan (GlcNAC) transferase
activities and their functions are indispensable for hepa-
rin-sulphate biosynthesis [10]. The nature of the tumour
suppressor effects of the heparan sulphate biosynthesis is
not entirely clear, however the regulation of Ihh signalling
was proposed to play an important role [11]. Here we
describe a family with 5 patients affected by osteopoikilo-
sis caused by novel mutation in the LEMD3 gene. Inter-
estingly, three of the patients affected with this new
LEMD3 mutation additionally carry a new mutation in
the EXT1 gene. We discuss possible implications.
Methods
Patients
W e studied a two-branch family of Polish descent. The
main branch comprised three generations with five indi-
viduals affected by osteopoikilosis. We also examined a
more distant kindred affected by the severe deforma-
tional condition of the long bones. The local ethics com-
mittee approved the study and written, informed consent
was obtained from all participants or their legal guardians
for publication of this case report, including clinical data,
pedigree and X-ray images. Copies of all written consents
are available for review on request.
DNA sequencing
The LEMD3 and EXT1 genes were analyzed by bidirec-
tional sequencing with primers listed in the see (Table 1).
PCR amplification of LEMD3 gene was performed in a 20
μl final volume, contained 1 U of Taq polymerase (FIRE
Pol) with buffer supplemented with 1.5 mM Mg2+, 0.4
mM dNTP, 8 pmol of each forward and reverse primer,
and 30 ng of DNA. The exons were amplified as follow-
ing: 5 min at 94°C, 35 cycles (30 sec 94°C, 30 sec 60°C, 30
sec 72°C) 10 min 72°C. PCR amplifications of EXT1 gene
were performed in a 20 μl final volume, contained 1 U of
Taq polymerase (Invitek) with buffer supplemented with
2 mM Mg2+, 0.4 mM dNTP, 8 pmol of each forward and
reverse primer, and 30 ng of DNA. PCR conditions used
were as in case of LEMD3, with exception of exon1-2 and
exon 6 amplification, where annealing temperature varied
from 55°C to 61°C (touchdown PCR). PCR products were
sequenced with the DNA Sequencing Kit BigDye™ Termi-
nator v3.0 Cycle Sequencing (Applied Biosystems) on an
ABI 3730 automated sequencer. All exons were compared
to genomic sequence (NM_014319.3 for LEMD3  gene
and NM_000127.2 for EXT1 gene) and variations were
numbered according to Ensembl ENSG00000174106 for
LEMD3 and ENSG00000182197 for EXT1. Healthy con-
trol subjects were screened for the identified mutations in
the LEMD3 and EXT1 genes via sequence analysis. cDNA
was synthesised using random hexamer primers as
described below. PCR amplification of the EXT1 cDNA
fragments was done with primer pairs listed in (Table 2).
The amplification conditions were like for the genomic
DNA sequencing. PCR products were sequenced with
the DNA Sequencing Kit BigDye™ Terminator v3.0 Cycle
Sequencing (Applied Biosystems) on an ABI 3730 auto-
mated sequencer.
Isolation of the primary osteoblast cells
Surgically removed exostosis was placed in alphaMEM
medium supplemented with 10% FCS, Penicilin-Strepto-
mycin and Glutamine and transported to laboratory
within 24 h. Bone was cleaned of any remaining connec-
tive tissue and 3 rounds of collagenase IV (2 mg/ml)
digest 1× 5 min. and 2× 20 min. each at 37°C were per-
formed. Cells from the first digestion were discarded
whereas second and third digests were pooled and seeded
in the alpha-MEM medium. Cells were cultured till con-
fluent.
RNA isolation and cDNA synthesis
Total RNA was isolated with peqGOLD TriFast™ reagent
(PeqLab) according to supplied protocol. cDNAs were
synthesised from 1 μg total RNAs with SuperscriptII
(Invitrogen) according to manufacturer's guidelines.Baasanjav et al. BMC Medical Genetics 2010, 11:110
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Results
Clinical History
In the current study we identified a family with congeni-
tal osteopoikilosis (Figure 1). The affected family mem-
bers suffered from moderate to intermittent pain in the
hands and feet, with onset of the symptoms varying from
15 (Patient IV:17) to 26 years of age (Patient III:13). X-ray
examination revealed disseminated sclerotic foci in the
bones of the hands and feet, in the epiphyseal parts of the
long bones as well as pelvis and sacrum (Figure 2). Clini-
cal features observed in the affected family members are
summarized in (Table 3), and involve several findings:
dermatofibrosis, tetralogy of fallot (TOF), ovarian and
sinus cysts, diabetes mellitus type 2, and vitiligo. Interest-
ingly these various features were presented by the
patients who carried both LEMD3 and EXT1 gene muta-
Table 1: Sequences of the primers used for LEMD3 and EXT1 gene amplification and sequencing.
Exon name F Primer sequence 5'- 3' R Primer sequence 5' - 3'
LEMD3_e1-1 CTCAGGTGAGCTCCTCCC CGACTCGTCCGAGCTGAAG
LEMD3_e1-2 GCGACCTCTCCTACTTACGG GTCGTCGTCGTCCTCTTCC
LEMD3_e1-3 AGGAGAGGGACCCGGAG GGGGAGTCCACACTGAAGG
LEMD3_e1-4 AGGAGGGTGTGATCAAGTGG GCGCAAATAGTCTTTCAGGG
LEMD3_e2 TTTAGCAAAGTACATGCTGGC TTATACGACAGTTAGGGAATACTCAG
LEMD3_e3 TTCAGATTATGTGGCTTCTGTG TTCACAAATATAACACTGGACTTGG
LEMD3_e4 TGTGGTTAATGTAATGGTAGTTGTTTG GGAACAAGAGCGAAACTGTG
LEMD3_e5-6 TTGGAGTAGTGGGAAAATGC GCTGTGACTTATGTGGCAACC
LEMD3_e7-8 GAAGGTTCATTCCGTTGTGG AGTTGAGAAGGGTCACAGCTC
LEMD3_e9 CATCTAAATCTTCTTTGAACAAACTCC CAGAACGAGAGAGTTTTGCC
LEMD3_e10 CTAACCAGGGGTCTGGCTC TTTGCTTGGAATTTAATGAAAGAG
LEMD3_e11-12 TCTACCTCCTGTTAGTCAACAAGC TGGTAAAAGACATATGAGCACAAAAC
LEMD3_e13 ATTGCATGGCTCTTGGTTTG GCTGCCTCACTGCTAAATCC
EXT1_e1-1 TCTTTACAGGCGGGAAGATG TGTTCCACAAGTGGAGACTCTG
EXT_e1-2 CCAGGTTCTACACCTCGGAC CTCAGTTCCAGGCTCAAAGG
EXT1_e2 CTGGTGGCTTTCCCGAG AAGGGAAACCACACCTTCTC
EXT1_e3 AAGCTTCCTTTCCTTCTGGC CCATGACACAGGTAATTTTCTCC
EXT1_e4 TGCTAGAAGCCAAATGCTATG TGGACCAATCACACATCCC
EXT1_e5 CTCTGACTGCCACCATCTTTC AAGCAATCTTCAATGCAGGG
EXT1_e6 ATTTGCTCCAGCATGAGGC TGAATGAAAGGGAGTAGCAGG
EXT1_e7 GCTGAGATTTCCAGCTCCTC AACAGGGAGAAGATATCTAGGGC
EXT1_e8 AGATTCCTTCGGTGTTGAGG CAAGGCACGGCTAAAAGAAG
EXT1_e9 CCGGATTTTGCATTATGAATTAG ATCAGCAAAACTTAAGCGGG
EXT1_e10 GGGATTCAAAGAATGGGTATG CTGGGTGGAACAGCTAGAGG
EXT1_e11 TGCTCATTTGCCTGACTCC ACAATCTGGCTCTGCTGATG
Table 2: Sequences of the primers used for EXT1 cDNA amplification and sequencing.
PCR name F Primer sequence 5'- 3' R Primer sequence 5' - 3'
EXT1 cDNA1 GCTGCTCGCCCGCCCTGGGTG GTGGTGCAAGCCATTCCTAC
EXT1 cDNA2 CTCAGCTGGCTCTTGTCTCG CTCGGTGTAGTCAGGCCAAG
EXT1 cDNA3 CTTGTGGAACAATGGTAGG CCTATGACGGCAGCTTGGTTC
EXT1 cDNA4 GTATGATTATCGGGAAATG CTGGGCACAGTACTGGGACTTGG
EXT1 cDNA5 CTGGTCTCTCAGTCCCAGC GTCCCATCATTGTCTCCTTATAC
EXT1 cDNA6 GCCTCCAATCAAAGTGACCC CTCTGCTGATGAGTGGATCTGCBaasanjav et al. BMC Medical Genetics 2010, 11:110
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tions (with exception of dermatofibrosis which was pre-
sented by a patient affected with LEMD3 mutation only).
We also consulted a more distant relative of this family
(V:1), who was independently referred to a clinical genet-
icist at the age of 7 years. X-ray examination showed large
multiple exostoses predominantly localized in the ends of
the long bones (Figure 2). The boy was operated at the
age of 7 years for a large exostosis affecting proximal part
of the right humerus. Histopathological examination of
the removed bone was suggestive of enchondromatosis.
Mutation Detection
Full coding sequence and exon-intron boundaries of the
LEMD3  gene were analyzed in the nine individuals.
Patients (III:10, III:13, IV:8, IV:15, IV:17) were heterozy-
gous for C-to-T transition in exon 9 (c.2203C > T) on
genomic DNA. This mutation was predicted to change
amino acid 735 from an arginine to a stop codon
(p.R735X) (Figure 1, Figure 3A). Three out of these
patients (III:13, IV:15, IV:17) additionally carried a
heterozygous mutation in the EXT1 gene. This mutation
Figure 1 Co-occurrence of LEMD3 and EXT1 mutations. (A) Co-occurrence of LEMD3 (*) and EXT1 missense mutation (α) in the family affected with 
osteopoikilosis. A 9 bp deletion in EXT1 gene (β) affecting patient suffering from multiple exostoses. (B) Representative electrophoregrams of the de-
tected mutations. Osteopoikilosis phenotype is shown in black, whereas multiple exostoses syndrome is represented with brown colour. Horizontal 
bars over symbols mark patients who underwent clinical examination and molecular testing.Baasanjav et al. BMC Medical Genetics 2010, 11:110
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altered G-to-A in exon 9 (c.1732G > A) on genomic DNA
and predicted to change amino acid 578 from an alanine
to a threonine (p.A578T). Presence of both LEMD3 and
EXT1 variants was excluded among 81 and 247 healthy
Polish and German controls respectively. Bioinformatic
analysis of the EXT1 sequence with SIFT http://
sift.jcvi.org and PolyPhen http://genetics.bwh.har-
vard.edu/pph/ software indicated a high probability of
the mutation being deleterious for the protein function
(PolyPhen - PSIC score difference for A578T: 1.688) - see
(Figure 3B) for sequence conservation. However, affected
patients did not exhibit exostoses and no additional skele-
tal manifestations beyond hyper-mineralized foci were
detected. Interestingly, patients affected with both
LEMD3  and  EXT1  mutations presented spectrum of
additional non-skeletal pathologies, which included:
(IV:15) TOF and ovarian cysts, (IV:17) sinus cysts, and
(III:13) diabetes melitus type 2 and vitiligo (Table 3).
A different mutation in EXT1 gene was identified in the
patient (V:1), diagnosed with multiple exostoses syn-
drome. The patient carried a heterozygotic splice site
mutation in intron 5 (IVS5-2 A > G), as detected in blood
lymphocytes and primary osteoblast progenitor cells
obtained from the surgically removed exostoses.
Sequencing of the exostoses derived cDNA (obtained
from the cells isolated from the affected bone) showed
that splice site mutation resulted in the in-frame deletion
of 9 bp of the exon 5 leading to a deletion of three amino
acids (pos. 429-431 - two conserved isoleucin residues
and a conserved glutamic acid residue) (Figure 3B). Func-
tional relevance of the deleted amino acids was predicted
based on their evolutionary conservation.
Discussion
We identified a family with five members affected by
osteopoikilosis caused by a novel nonsense heterozygous
mutation (p.R735X) localised in exon 9 of the LEMD3
gene. In other branch of this family we identified a boy
affected by more severe bone deformations. The boy was
initially suspected of the melorheostosis, but upon X-ray
examination, the diagnosis was corrected to the multiple
exostoses syndrome. Clinical diagnosis was subsequently
confirmed by sequence analysis of the EXT1 gene and
identification of a previously undescribed splice site
mutation (IVS5-2 A>G). This finding led us to sequence
EXT1 gene in the rest of the family. Surprisingly, three of
the osteopoikilosis affected patients additionally to
Figure 2 Sclerotic changes in the hands, feet, and pelvis of the os-
teopoikilosis affected patients positive for c.2203C > T (p.R735X) 
LEMD3 mutation. (A) Hyperostotic spots are seen bilaterally in the dis-
tal parts of radius and carpal bones (arrows) as well as in the phalanges 
of hands and feet and in the pelvis (arrowheads). (B) Radiological ap-
pearance of the right hand of the proband (V:I - carrying intron 5 IVS5-
2 A > G mutation) at the age of 5 years. Large exostoses in the proximal 
part of the humerus, as well as in the proximal and distal ends of the 
ulna and radius are demarcated with arrows.
Table 3: Clinical symptoms identified in the patients presenting with osteopoikilosis.
Patient IV:15 Patient IV:17 Patient III:13 Patient III:10 Patient IV:8
(female; 26 years) (female; 24 years) (male; 60 years) (female; 54 years) (male; 19 years)
EXT1 mutation status p.A578T p.A578T p.A578T - -
P a i n f u l  h a n d s  a n d  f e e t +++++
D e r m a t o f i b r o s i s ---+-
Additional skin changes - - Vitiligo - -
Other symptoms/disorders TOF, Ovarian cyst Sinus cyst DM2 - -
Laboratory tests (Ca, P, AP, ACP) NE NE NE Normal NE
TOF - tetralogy of Fallot; DM2 - diabetes mellitus type 2; NE - not examined; Ca - calcium; P - phosphate; AP - alkaline phosphatase; ACP - acid 
phosphataseBaasanjav et al. BMC Medical Genetics 2010, 11:110
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Figure 3 Schematic representation of the LEMD3 and EXT1 protein structure with the protein motifs and domains assigned. (A) The LEMD3 
R735X (*) mutation localizes in SMAD binding domain of LEMD3. EXT1 mutation A578T (α) localizes in the glycotransferase domain of EXT1. EXT1 mu-
tation IVS5-2 A > G (p. DEL 429-431) (β) is located in the conserved region of the protein in-between two catalytically active domains. (B) Evolutionary 
conservation of the mutated amino acid residues in the EXT1. The block of absolute sequence conservation surrounding mutation sites is demarcated 
with the red bracket.Baasanjav et al. BMC Medical Genetics 2010, 11:110
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LEMD3 mutation carried a yet unreported amino acid
variant (p.A578T) in the EXT1 gene. Of note was a wide
spectrum of the clinical symptoms observed in these
family members, which ranged from heart defect, diabe-
tes mellitus, vitiligo to ovarian and sinus cyst formation.
None of these pathologies was observed in the examined
family members who carried LEMD3  mutation only
(patients III:10 and IV:8), nor in the family members who
were free of mutations in both genes (patients III:5, III:8,
III:14, IV:3). However, since we were unable to examine
other unaffected family members, the relevance of this
observation remains uncertain. The EXT1  splice site
mutation and other identified mutations must have
occurred independently in the two branches of the family.
The exact mechanism by which LEMD3 gene muta-
tions lead to the formation of the bone lesions is not clear.
LEMD3 inactivation in mice was recently shown to result
in the mid-gestation lethality [12]. However, heterozy-
gous mice were healthy and no bone lesions reminiscent
of osteopoikilosis could be detected, leaving question
mark over patho-mechanism of the disease. Co-occur-
rence of the LEMD3 gene mutation with the mutation in
another gene has not yet been reported. Presented case
constitutes first such report. Following considerations
appear relevant based on the review of the available liter-
ature. It has been shown that LEM domain containing
proteins interact with the barrier-to-autointegration fac-
tor (BAF) [13]. BAF is a component of the chromatin
r e m o d e l l i n g  c o m p l e x,  w h i c h  u s e s  e n e r g y  f r o m  A T P  t o
dismantle DNA-histone complexes [14]. This is on one
hand necessary for initiation of transcription, and it has
been postulated that LEMD3, through BAF and SMAD
interactions might regulate the expression of osteogenic
genes [2]. On the other hand it is known that chromatin
remodelling is necessary for the efficient DNA repair
[15]. LEMD3 closely associates with the intranuclear lam-
ina and mutations in other lamin interacting proteins are
known to result in the DNA damage accumulation [16].
Indeed, it has been suggested that lamin complexes acts
as assembly scaffolds for DNA repair machinery [17].
Thus, it seems legitimate to ask if inactivation of LEMD3
could also result in an increased mutational susceptibility
and increased frequency of the post-zygotic second hit
mutation occurrence. In this context it is interesting to
note that osteopoikilosis was previously reported to coin-
cide with other pathological entities, including various
types of cancers: synovial chondromatosis [18], syn-
oviosarcoma [19], chondrosarcoma [20], osteosarcoma
[21], giant cell tumor [22], metastatic breast carcinoma
[23], as well as developmental dysplasias: dental, facial
abnormalities, coarctation of the aorta, double urether,
mental retardation and other reviewed by Gunal et.al.
[24].
Clearly, further research is needed to address possible
association of the LEMD3  loss of function with DNA
mutation susceptibility. Presented study constitutes first
example of the LEMD3  gene mutation co-occurrence
with additional genetic alteration, which could potentially
modify and/or constitute the nature of the osteopoikilo-
sis.
Conclusions
The presented case points to importance of the thorough
clinical evaluation of the osteopoikilosis patients as phe-
notypic features of osteopoikilosis with melorheostosis
might be confused with the co-occurrence of osteopoiki-
losis and multiple exostoses. The data encourage re-eval-
uation of the known osteopoikilosis families for the
possible co-occurrence of other than Buschke-Ollendorff
and melorheostosis disease entities and investigation of
the possible LEMD3 function in the DNA repair.
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